Cosmo Pharmaceuticals (OTCMKTS:CMOPF) Shares Down 2.1% – What’s Next?

Cosmo Pharmaceuticals (OTCMKTS:CMOPF)’s stock price dropped 2.1% during trading on Wednesday . The stock traded as low as C$81.48 and last traded at C$83.25. Approximately 400 shares changed hands during trading, a decline of 5% from the average daily volume of 423 shares. The stock had previously closed at C$85.02.

Cosmo Pharmaceuticals Stock Down 2.1%

The business’s fifty day simple moving average is C$100.13 and its two-hundred day simple moving average is C$120.86.

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.